vs

Side-by-side financial comparison of CITIZENS FINANCIAL SERVICES INC (CZFS) and PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB). Click either name above to swap in a different company.

PACIFIC BIOSCIENCES OF CALIFORNIA, INC. is the larger business by last-quarter revenue ($44.6M vs $29.6M, roughly 1.5× CITIZENS FINANCIAL SERVICES INC). CITIZENS FINANCIAL SERVICES INC runs the higher net margin — 35.4% vs -90.4%, a 125.8% gap on every dollar of revenue. On growth, PACIFIC BIOSCIENCES OF CALIFORNIA, INC. posted the faster year-over-year revenue change (13.8% vs 13.0%). CITIZENS FINANCIAL SERVICES INC produced more free cash flow last quarter ($35.2M vs $-19.9M). Over the past eight quarters, PACIFIC BIOSCIENCES OF CALIFORNIA, INC.'s revenue compounded faster (7.3% CAGR vs 6.9%).

Citizens Financial Group, Inc. is an American bank holding company, headquartered in Providence, Rhode Island. The company owns the bank Citizens Bank, N.A., which operates in the U.S. states of Connecticut, Delaware, Florida, Maryland, Massachusetts, Michigan, New Hampshire, New Jersey, New York, Ohio, Pennsylvania, Rhode Island, Vermont, and Virginia, as well as Washington, DC.

Pacific Biosciences of California, Inc. is an American biotechnology company founded in 2004 that develops and manufactures systems for gene sequencing and some novel real time biological observation. PacBio has two principal sequencing platforms: single-molecule real-time sequencing (SMRT), based on the properties of zero-mode waveguides and sequencing by binding (SBB) chemistry, which uses native nucleotides and scarless incorporation for DNA binding and extension.

CZFS vs PACB — Head-to-Head

Bigger by revenue
PACB
PACB
1.5× larger
PACB
$44.6M
$29.6M
CZFS
Growing faster (revenue YoY)
PACB
PACB
+0.9% gap
PACB
13.8%
13.0%
CZFS
Higher net margin
CZFS
CZFS
125.8% more per $
CZFS
35.4%
-90.4%
PACB
More free cash flow
CZFS
CZFS
$55.2M more FCF
CZFS
$35.2M
$-19.9M
PACB
Faster 2-yr revenue CAGR
PACB
PACB
Annualised
PACB
7.3%
6.9%
CZFS

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
CZFS
CZFS
PACB
PACB
Revenue
$29.6M
$44.6M
Net Profit
$10.5M
$-40.4M
Gross Margin
37.1%
Operating Margin
44.2%
-92.3%
Net Margin
35.4%
-90.4%
Revenue YoY
13.0%
13.8%
Net Profit YoY
31.3%
-1802.7%
EPS (diluted)
$2.17
$-0.11

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CZFS
CZFS
PACB
PACB
Q4 25
$29.6M
$44.6M
Q3 25
$29.0M
$38.4M
Q2 25
$27.3M
$39.8M
Q1 25
$26.4M
$37.2M
Q4 24
$26.2M
$39.2M
Q3 24
$25.1M
$40.0M
Q2 24
$24.6M
$36.0M
Q1 24
$25.9M
$38.8M
Net Profit
CZFS
CZFS
PACB
PACB
Q4 25
$10.5M
$-40.4M
Q3 25
$10.0M
$-38.0M
Q2 25
$8.5M
$-41.9M
Q1 25
$7.6M
$-426.1M
Q4 24
$8.0M
$2.4M
Q3 24
$7.5M
$-60.7M
Q2 24
$5.3M
$-173.3M
Q1 24
$7.0M
$-78.2M
Gross Margin
CZFS
CZFS
PACB
PACB
Q4 25
37.1%
Q3 25
41.4%
Q2 25
36.9%
Q1 25
-3.7%
Q4 24
25.6%
Q3 24
25.0%
Q2 24
16.5%
Q1 24
29.1%
Operating Margin
CZFS
CZFS
PACB
PACB
Q4 25
44.2%
-92.3%
Q3 25
42.6%
-101.1%
Q2 25
38.1%
-112.8%
Q1 25
35.5%
-1154.5%
Q4 24
37.2%
-390.1%
Q3 24
36.9%
-160.3%
Q2 24
25.9%
-488.3%
Q1 24
32.8%
-209.6%
Net Margin
CZFS
CZFS
PACB
PACB
Q4 25
35.4%
-90.4%
Q3 25
34.5%
-98.9%
Q2 25
31.0%
-105.4%
Q1 25
28.8%
-1146.8%
Q4 24
30.5%
6.0%
Q3 24
30.0%
-151.9%
Q2 24
21.4%
-481.3%
Q1 24
27.1%
-201.4%
EPS (diluted)
CZFS
CZFS
PACB
PACB
Q4 25
$2.17
$-0.11
Q3 25
$2.09
$-0.13
Q2 25
$1.76
$-0.14
Q1 25
$1.60
$-1.44
Q4 24
$1.64
$-0.44
Q3 24
$1.57
$-0.22
Q2 24
$1.10
$-0.64
Q1 24
$1.48
$-0.29

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CZFS
CZFS
PACB
PACB
Cash + ST InvestmentsLiquidity on hand
$34.3M
$279.5M
Total DebtLower is stronger
Stockholders' EquityBook value
$338.1M
$5.3M
Total Assets
$3.1B
$784.1M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CZFS
CZFS
PACB
PACB
Q4 25
$34.3M
$279.5M
Q3 25
$31.1M
$298.7M
Q2 25
$49.5M
$314.7M
Q1 25
$36.8M
$343.1M
Q4 24
$42.2M
$389.9M
Q3 24
$36.8M
$471.1M
Q2 24
$38.4M
$509.8M
Q1 24
$29.6M
$561.9M
Stockholders' Equity
CZFS
CZFS
PACB
PACB
Q4 25
$338.1M
$5.3M
Q3 25
$327.7M
$36.1M
Q2 25
$313.7M
$61.5M
Q1 25
$308.3M
$91.6M
Q4 24
$299.7M
$506.6M
Q3 24
$298.7M
$453.1M
Q2 24
$286.5M
$492.7M
Q1 24
$282.7M
$649.0M
Total Assets
CZFS
CZFS
PACB
PACB
Q4 25
$3.1B
$784.1M
Q3 25
$3.1B
$803.2M
Q2 25
$3.0B
$825.5M
Q1 25
$3.0B
$860.8M
Q4 24
$3.0B
$1.3B
Q3 24
$3.0B
$1.5B
Q2 24
$2.9B
$1.5B
Q1 24
$2.9B
$1.7B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CZFS
CZFS
PACB
PACB
Operating Cash FlowLast quarter
$36.5M
$-19.1M
Free Cash FlowOCF − Capex
$35.2M
$-19.9M
FCF MarginFCF / Revenue
119.0%
-44.6%
Capex IntensityCapex / Revenue
4.4%
1.9%
Cash ConversionOCF / Net Profit
3.49×
TTM Free Cash FlowTrailing 4 quarters
$53.8M
$-114.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CZFS
CZFS
PACB
PACB
Q4 25
$36.5M
$-19.1M
Q3 25
$2.9M
$-18.7M
Q2 25
$6.0M
$-29.4M
Q1 25
$10.9M
$-44.1M
Q4 24
$33.2M
$-30.6M
Q3 24
$6.2M
$-45.5M
Q2 24
$3.0M
$-54.3M
Q1 24
$13.5M
$-75.7M
Free Cash Flow
CZFS
CZFS
PACB
PACB
Q4 25
$35.2M
$-19.9M
Q3 25
$2.7M
$-18.8M
Q2 25
$5.5M
$-29.9M
Q1 25
$10.4M
$-45.4M
Q4 24
$31.9M
$-32.3M
Q3 24
$5.6M
$-46.3M
Q2 24
$2.9M
$-55.7M
Q1 24
$13.4M
$-79.6M
FCF Margin
CZFS
CZFS
PACB
PACB
Q4 25
119.0%
-44.6%
Q3 25
9.4%
-48.9%
Q2 25
20.1%
-75.3%
Q1 25
39.2%
-122.3%
Q4 24
121.6%
-82.3%
Q3 24
22.3%
-115.7%
Q2 24
11.8%
-154.8%
Q1 24
51.5%
-205.0%
Capex Intensity
CZFS
CZFS
PACB
PACB
Q4 25
4.4%
1.9%
Q3 25
0.5%
0.2%
Q2 25
1.8%
1.4%
Q1 25
2.2%
3.7%
Q4 24
5.0%
4.1%
Q3 24
2.5%
2.0%
Q2 24
0.5%
4.1%
Q1 24
0.4%
10.0%
Cash Conversion
CZFS
CZFS
PACB
PACB
Q4 25
3.49×
Q3 25
0.29×
Q2 25
0.71×
Q1 25
1.44×
Q4 24
4.16×
-12.93×
Q3 24
0.83×
Q2 24
0.57×
Q1 24
1.92×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CZFS
CZFS

Segment breakdown not available.

PACB
PACB

Products$39.0M87%
Service And Other$5.7M13%

Related Comparisons